Targeting the root cause of Rheumatoid Arthritis with new peptide drugs with low side-effect profile

Targeting the root cause of Rheumatoid Arthritis with new peptide drugs with low side-effect profile

Targeting the root cause of Rheumatoid Arthritis with new peptide drugs with low side-effect profiles


Dr. John Trant

University of Windsor

 

The overall goal of the research is to create custom-tailored peptide drugs that block the molecular event that initiates and propagates the autoimmune response: the binding of a self-peptide by human leukocyte antigen (HLA) receptors. This strategy could provide a cure for all autoimmune diseases. This grant focuses on RA as a starting point: the specific peptides made in this grant would benefit 240,000 Canadians, 65% of all RA patients.

Related Programs:
Nucleus Cores:

FUNDER:

New Frontier in Research Fund (NFRF)

GRANT DURATION:

2019-2021

 

Loading...